Брилид

Infections of the respiratory tract and ENT organs: tonsillitis, pharyngitis, sinusitis, diphtheria, pertussis, otitis media, SARS, chronic obstructive pulmonary diseases, bronchitis (acute and exacerbation of chronic), panbronchitis, bronchiectasis, infections of the genitourinary system (non-gonococcal urethritis, chlamydial gynecological infections), osteomyelitis, prevention of meningococcal meningitis.

Inside, before meals, adults 0.15 g 2 times a day or 0.3 g once, with severe renal insufficiency-0.15 g/day. The duration of the course is determined individually, depending on the severity of the infectious process (from 5-12 days in acute diseases of the respiratory tract and ENT organs and up to 2-2.5 months in chronic osteomyelitis). Children — 0.005-0.008 mg/kg / day in 2 doses for no more than 10 days.

Hypersensitivity (including to other macrolides), severe hepatic impairment, pregnancy, breast-feeding, infant age up to 2 months.

Contraindicated. Breastfeeding should be discontinued for the duration of treatment.

From the nervous system and sensory organs: dizziness, headache, weakness, malaise, impaired vision and sense of smell, tinnitus, change in taste.

From the gastrointestinal tract: abdominal pain, dyspepsia, anorexia, flatulence, nausea, vomiting, constipation or diarrhea, symptoms of pancreatitis.

Allergic reactions: rash, itching, urticaria, bronchospasm, anaphylactic shock.

Other: eczema, superinfection, oral and vaginal candidiasis.

Active against group A and B streptococci, resistant to beta-lactamases.

It is rapidly absorbed from the gastrointestinal tract and is detected in the plasma after 15 minutes (the presence of food slows the rate of absorption, but does not affect its completeness). C_max it is achieved after 1.5-2 hours and at a dose of 0.15 g is 6.6 mg/l. Binding to plasma proteins-up to 96%, quickly distributed in the tissues of the respiratory tract (especially the lungs), tonsils, prostate, ovaries, kidneys, liver. When taken at a dose of 0.15 g 2 times a day, the equilibrium concentration is reached after 2-4 days. It is excreted unchanged and in the form of metabolites mainly through the gastrointestinal tract, partially by the lungs (15%), kidneys (up to 10%) and with breast milk (less than 0.05%). Average T_1/2 - 10.5 hours — It does not accumulate.

• Macrolides and azalides

Incompatible with ergotamine-like drugs (probably the development of ergotism and necrosis of the tissues of the extremities). Increases the absorption of digoxin, the bioavailability of omeprazole (mutually), the probability of toxic effects of theophylline, midazolam, triazolam. Displaces disopyramide from complexes with plasma proteins, increases the concentration of astemizole and pimozide in the serum (accompanied by an extension of the QT interval of the ECG or severe arrhythmias).

In a dry place, protected from light, at a temperature not exceeding 30 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 tablet, coated, contains roxithromycin 0.15 g, in a contour cell package of 10 pcs. , in a cardboard pack of 1 package.

J01FA06 the Roxithromycin

• A36. 9 Diphtheria, unspecified
• A37 Whooping cough
• A39. 0 Meningococcal meningitis
• A56. 1 Chlamydial infections of the pelvic organs and other genitourinary organs
• A56. 2 Chlamydia infection of the genitourinary tract, unspecified
• H60 Otitis externa
• H65 Non-purulent otitis media
• I33 Acute and subacute endocarditis
• J06 Acute upper respiratory tract infections of multiple and unspecified localization
• J18 Pneumonia without specifying the causative agent
• J20 Acute bronchitis
• J44. 9 Chronic obstructive pulmonary disease, unspecified
• J47 Bronchiectatic disease [bronchiectasis]
• M86 Osteomyelitis
• N34. 1 Non-specific urethritis
• N39. 0 Urinary tract infection without established localization
• N73. 9 Inflammatory diseases of the female pelvic organs, unspecified
• R78. 8. 0 * Bacteremia
• Z100* CLASS XXII Surgical Practice